SCHEMBL2849753

SCHEMBL2849753

CCOC(=O)N1CCC(n2ncc3ccccc32)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.61
TSHR P16473 2/20 0.61
POLB P06746 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.54
KDM4E B2RXH2 6/20 0.53
ALDH1A1 P00352 5/20 0.53
NOS2 P35228 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 1/20 0.51
HTT P42858 1/20 0.51
KDM5A P29375 1/20 0.51
CHRM2 P08172 1/20 0.50
CHRM4 P08173 1/20 0.50
CHRM5 P08912 1/20 0.50
CHRM1 P11229 1/20 0.50
CHRM3 P20309 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7804097 0.80 KMT2A (0.51) HSD17B10TSHRPOLBL3MBTL1KDM4E
SCHEMBL7804080 0.80 KDM4E (0.52) L3MBTL1KDM4EALDH1A1SMN1; SMN2LMNA
SCHEMBL2856965 0.78 L3MBTL1 (0.54) HSD17B10TSHRL3MBTL1KDM4EALDH1A1
SCHEMBL3145435 0.78 DRD2 (0.59) HSD17B10TSHRPOLBL3MBTL1KDM4E
SCHEMBL17092683 0.76 GPR119 (0.61) POLBALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL13135671 0.76 SCD (0.56) SMN1; SMN2KDM5ACHRM2CHRM4CHRM5
SCHEMBL17404486 0.75 DDB1 (0.53) TSHRL3MBTL1SMN1; SMN2KDM5ACHRM2
SCHEMBL29150097 0.74 L3MBTL1 (0.52) HSD17B10TSHRL3MBTL1KDM4EALDH1A1
SCHEMBL31381555 0.74 HSD17B10 (0.47) HSD17B10TSHRPOLBL3MBTL1KDM4E
SCHEMBL13319010 0.74 CHRM2 (0.53) HSD17B10TSHRL3MBTL1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 HSD17B10 376/4885TSHR 602/4885POLB 4577/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 HSD17B10 318/4885TSHR 722/4885POLB 4576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.